LU85716A1 - Procede de preparation d'un nouveau compose complexe d'hemine ayant des applications medicales - Google Patents
Procede de preparation d'un nouveau compose complexe d'hemine ayant des applications medicales Download PDFInfo
- Publication number
- LU85716A1 LU85716A1 LU85716A LU85716A LU85716A1 LU 85716 A1 LU85716 A1 LU 85716A1 LU 85716 A LU85716 A LU 85716A LU 85716 A LU85716 A LU 85716A LU 85716 A1 LU85716 A1 LU 85716A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- hemin
- water
- arginine
- preparation
- arginate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000008569 process Effects 0.000 title claims description 8
- -1 HEMINE COMPOUND Chemical class 0.000 title claims description 6
- 229940025294 hemin Drugs 0.000 claims description 85
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 15
- 229930064664 L-arginine Natural products 0.000 claims description 15
- 235000014852 L-arginine Nutrition 0.000 claims description 15
- 241000097929 Porphyria Species 0.000 claims description 13
- 208000010642 Porphyrias Diseases 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 32
- 229910052742 iron Inorganic materials 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 102000004020 Oxygenases Human genes 0.000 description 6
- 108090000417 Oxygenases Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 206010022971 Iron Deficiencies Diseases 0.000 description 5
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 5
- 201000005060 thrombophlebitis Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000031162 sideroblastic anemia Diseases 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940109738 hematin Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 2
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 108010067549 Methemalbumin Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000320 mechanical mixture Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010017500 Biliverdin reductase Proteins 0.000 description 1
- 244000208235 Borassus flabellifer Species 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 description 1
- 239000005569 Iron sulphate Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000004558 biliverdin reductase Human genes 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108060003196 globin Chemical group 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000004550 soluble concentrate Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8431398 | 1984-12-12 | ||
| GB08431398A GB2168354B (en) | 1984-12-12 | 1984-12-12 | Hemin compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU85716A1 true LU85716A1 (fr) | 1985-07-24 |
Family
ID=10571084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU85716A LU85716A1 (fr) | 1984-12-12 | 1984-12-28 | Procede de preparation d'un nouveau compose complexe d'hemine ayant des applications medicales |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPH0647541B2 (ja) |
| AT (1) | AT389308B (ja) |
| BE (1) | BE901319A (ja) |
| CA (1) | CA1242713A (ja) |
| CH (1) | CH666273A5 (ja) |
| DE (1) | DE3446887C2 (ja) |
| FR (1) | FR2574662B1 (ja) |
| GB (1) | GB2168354B (ja) |
| LU (1) | LU85716A1 (ja) |
| NL (1) | NL192682C (ja) |
| SE (1) | SE457958B (ja) |
| SU (1) | SU1384188A3 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0645681B2 (ja) * | 1986-02-05 | 1994-06-15 | 美浜 久春 | 修飾ヘム |
| IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| US7994217B2 (en) * | 2002-05-02 | 2011-08-09 | Xanodyne Pharmaceuticals, Inc. | Prenatal multivitamin/multimineral supplement |
| RU2611636C1 (ru) * | 2016-02-25 | 2017-02-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования Новосибирский государственный аграрный университет | Гематоген |
| RU2671633C1 (ru) * | 2017-11-30 | 2018-11-06 | Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" | Высокоэффективный гематоген |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912M (fr) * | 1963-07-24 | 1964-11-09 | Rech S Pharma E R P H A R Soc | Dichlorhydrate d'hématoporphyrinate de procaine. |
| JPS4930521A (ja) * | 1972-07-17 | 1974-03-19 | ||
| JPS5144623A (ja) * | 1974-10-14 | 1976-04-16 | Green Cross Corp | Chushayoasechirusarichirusanenno seiho |
| DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| JPS5780317A (en) * | 1980-11-05 | 1982-05-19 | Sumitomo Chem Co Ltd | Preparation of pharmaceutical composition for injection |
| JPS57209211A (en) * | 1981-06-18 | 1982-12-22 | Shiseido Co Ltd | Antimicrobial composition |
-
1984
- 1984-12-10 SE SE8406263A patent/SE457958B/sv not_active IP Right Cessation
- 1984-12-10 AT AT0390784A patent/AT389308B/de not_active IP Right Cessation
- 1984-12-12 GB GB08431398A patent/GB2168354B/en not_active Expired
- 1984-12-13 NL NL8403782A patent/NL192682C/nl not_active IP Right Cessation
- 1984-12-14 FR FR848419134A patent/FR2574662B1/fr not_active Expired - Lifetime
- 1984-12-19 BE BE0/214195A patent/BE901319A/fr not_active IP Right Cessation
- 1984-12-21 DE DE3446887A patent/DE3446887C2/de not_active Expired - Fee Related
- 1984-12-28 LU LU85716A patent/LU85716A1/fr unknown
-
1985
- 1985-01-07 CH CH45/85A patent/CH666273A5/de not_active IP Right Cessation
- 1985-01-09 SU SU3831925A patent/SU1384188A3/ru active
- 1985-01-23 JP JP60009302A patent/JPH0647541B2/ja not_active Expired - Fee Related
- 1985-02-06 CA CA000473658A patent/CA1242713A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ATA390784A (de) | 1989-04-15 |
| SE457958B (sv) | 1989-02-13 |
| SE8406263D0 (sv) | 1984-12-10 |
| SU1384188A3 (ru) | 1988-03-23 |
| BE901319A (fr) | 1985-04-16 |
| GB2168354A (en) | 1986-06-18 |
| GB2168354B (en) | 1988-12-07 |
| NL192682B (nl) | 1997-08-01 |
| JPH0647541B2 (ja) | 1994-06-22 |
| CH666273A5 (de) | 1988-07-15 |
| SE8406263L (sv) | 1986-06-11 |
| NL192682C (nl) | 1997-12-02 |
| DE3446887C2 (de) | 1994-05-05 |
| GB8431398D0 (en) | 1985-01-23 |
| FR2574662B1 (fr) | 1990-03-02 |
| DE3446887A1 (de) | 1986-07-03 |
| NL8403782A (nl) | 1986-07-01 |
| AT389308B (de) | 1989-11-27 |
| CA1242713A (en) | 1988-10-04 |
| FR2574662A1 (fr) | 1986-06-20 |
| JPS61172821A (ja) | 1986-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233106B1 (fr) | (-)-Benzhydrylsulfinylacétamide, procédé de préparation et utilisation en thérapeutique | |
| EP0316993A1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| FI68970C (fi) | Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening | |
| LU85716A1 (fr) | Procede de preparation d'un nouveau compose complexe d'hemine ayant des applications medicales | |
| BE1001621A3 (fr) | Nouveaux derives de l'acide furannuronique, leur preparation et leur utilisation comme medicaments. | |
| FR2548187A1 (fr) | Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides | |
| EP0069674A1 (fr) | Médicaments contenant une N-acyl-L-aspartyl-taurine | |
| WO1993014751A1 (fr) | Compositions pharmaceutiques contenant comme principe actif des associations de vanadium et/ou de niobium avec des derives du pyrocatechol | |
| FR2801055A1 (fr) | Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique | |
| CA2339878A1 (fr) | Utilisation des calix(n)arenes pour le traitement des maladies fibrotiques | |
| CH675725A5 (ja) | ||
| FR2686511A1 (fr) | Composition pharmaceutique contenant des associations de vanadium et/ou de niobium avec des acides amines ou des derives d'acides amines. | |
| CS247187B2 (cs) | Způsob výroby nového horninového komplexu | |
| CN109925279B (zh) | 一种硫辛酸注射液及其制备方法 | |
| EP0126012B1 (fr) | Compositions pharmaceutiques à base de disulfures symétriques | |
| FR2546168A1 (fr) | Dithiodiacetamides cycliques, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| FR2641465A1 (fr) | Nouveau capteur de radicaux libres et les compositions pharmaceutiques en contenant | |
| DD249028A5 (de) | Verfahren zur herstellung einer neuen haemin-komplexverbindung mit medizinischer verwendbarkeit | |
| FR2485372A1 (fr) | Composition pharmaceutique pour le traitement des etats d'intoxication alcoolique aigue a base de 5-oxo-2-pyrrolidone carboxylate de pyridoxine et procede de preparation de ce dernier | |
| WO1991007406A1 (fr) | Derives de metal de transition a structure porphyrinique, utilisation de ce derive pour la fabrication de medicaments | |
| EP0039265A1 (fr) | Nouveau médicament à base de biflavanone | |
| WO2004043983A1 (fr) | Derive du 4-methyl-2-oxo-2h-1-benzopyran-7yl 5-thio-beta-d-xylopyranoside, son procede de preparation et composition pharmaceutique le contenant | |
| WO2004111019A2 (fr) | Groupement protecteur clivable par les albumines seriques | |
| BE650426A (ja) | ||
| EP0624092A1 (fr) | Utilisation des derives du niobium comme principe actif de medicaments utiles dans le traitement et/ou la prevention des desordres du metabolisme des glucides et/ou des lipides |